Background: In the contemporary era of drug-eluting stents (DES) the issue of optimal revascularization strategy for patients with isolated disease of the left anterior descending (LAD) artery has gained more significance. We aimed to evaluate the current best evidence on the subject by performing a systematic review and meta-analysis of the studies comparing minimally invasive direct coronary artery bypass (MIDCAB) grafting with DES in patients with isolated LAD disease.
Introduction
Percutaneous coronary intervention with stents and minimally invasive direct coronary artery bypass (MIDCAB) grafting are well-established strategies for patients with isolated proximal stenosis of left anterior descending (LAD) artery (1) . However, several studies published in literature have consistently proven that the incidence of mediumterm adverse events and repeat revascularization of the target lesion were higher after percutaneous intervention with bare metal stents than MIDCAB in these patients (2) (3) (4) (5) . The introduction of drug-eluting stents (DES) in clinical practice has shown a great deal of promise for the treatment of both de novo and restenotic lesions, with reduction in instent neointimal proliferation that causes restenosis, thereby reducing the incidence of symptomatic recurrence to less than 5%, rivaling that of bypass surgery (6) .
Currently, the evidence comparing DES with MIDCAB is limited to only a small number of studies with small sample sizes, divergent designs and conflicting results. Each one of these studies provides a piece of evidence that, when taken together with others, addresses important questions for patients, clinicians, and other healthcare decision-makers. In the current era of evidence-based medicine, pairwise meta-analyses are increasingly used to synthesize the results of different trials evaluating the same intervention(s) to obtain an overall estimate of the treatment effect of one intervention relative to the control (7) . We aimed to evaluate the current best evidence by performing a systematic review and meta-analysis of the studies comparing the efficacy of MIDCAB with DES in patients with isolated LAD disease.
Methods

Literature search strategy
MEDLINE, EMBASE, Cochrane Controlled Trials
Register (CCTR), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), Science Citation Index (SCI), Current Contents, NHS Economic Evaluation Database (NEED), and International Network of Agencies for Health Technology Assessment (INAHTA) databases were searched from the date of their inception to March 10, 2018, using the search terms: (drug eluting stent or DES or percutaneous coronary intervention or PCI) AND (minimally invasive direct coronary artery bypass grafting or MIDCAB or left internal mammary artery or LIMA) AND (left anterior descending or LAD). The search was undertaken in accordance with Cochrane Collaboration recommendations (8) and was aimed at finding all published reports comparing MIDCAB with percutaneous coronary intervention using DES for revascularization of patients with isolated LAD stenosis. Articles written in English only were included. Tangential electronic exploration of related articles and hand searches of bibliographies, scientific meeting abstracts, and related journals were also performed.
Eligibility criteria
Studies written in English only comparing MIDCAB with percutaneous coronary intervention using DES recruiting participants with isolated proximal LAD disease evaluating one or more of the following outcomes: mortality, myocardial infarction (MI), target vessel revascularization (TVR) or a composite outcome namely major adverse cardiac and cerebrovascular events (MACCE) were included.
Studies recruiting participants with multivessel disease, studies where PCI was undertaken using bare metal stents, and reviews with no original data were excluded.
Data extraction and critical appraisal
The search results were reviewed by two independent judicators (SG, GS) for studies that met the inclusion criteria. The studies identified were validated by SGR. The studies fulfilling the inclusion criteria found by the search strategy were then evaluated. Each paper was subjected to a structured analysis using critical appraisal checklists (9) . Such checklists are widely available in several formats and are helpful in assessing the methodological and analytical soundness of a trial and in uncovering any serious methodological flaws (9) . The information extracted from each study included the study design, country, year of study, number of participants, age of participants, percentage of male participants, participant selection criteria, stent type, operation, outcomes, follow-up, and key outcomes.
Statistical analysis
Data from the individual eligible studies were entered into a spreadsheet for further analysis. Weighted mean differences (WMD) were calculated for the effect size of continuous variables. Pooled odds ratios (OR) were calculated for discrete variables such as mortality rates. The random-effects models (DerSimonian Laird) were used to calculate the outcomes of both binary and continuous data to control any heterogeneity between the studies. Heterogeneity amongst the trials was determined by means of the Cochran Q value and quantified using the I 2 inconsistency test. In this study, we did not perform meta-regression or sensitivity analysis because of the small number of studies included.
All P values were 2-sided and a 5% level was considered significant. StatsDirect 2.5.7 (StatsDirect, Altrincham, UK) was used to perform the statistical analysis.
Results
Quantity of evidence
Our search yielded 332 relevant reports, and after screening and reviewing full manuscripts, 12 studies met the inclusion criteria (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . The process of study selection is shown in Figure 1 . There were a total of 7,710 patients with 2,553 in the MIDCAB group compared to 5,157 in the DES group.
Quality of evidence
The study designs and participant characteristics of the included studies are listed in Tables 1,2 . There were three randomized controlled trials (RCTs) (11, 18, 21) and nine cohort studies (10, (12) (13) (14) (15) (16) (17) 19, 20) . Most studies had >100 participants in each arm except for four studies (11, 14, 18, 21) . Six retrospective studies reported reliable methods for ascertaining outcomes (10) (11) (12) (13) (14) 20) , whereas the remaining studies did not report how outcomes were ascertained. All three RCTs (11, 18, 21) had similar baseline characteristics among participants.
Assessment of outcomes
Study outcomes are listed in Table 3 Mortality Ten studies reported on the mortality rate. There were 2,334 patients in the MIDCAB group and 5,042 patients in the DES group. There was no statistical heterogeneity between studies (Cochran Q =16.0, P=0.07; I²=43.8%, 95% CI, 0% to 71.5%). In the random effects model, there was no significant difference in the mortality rates between the MIDCAB and DES groups [pooled OR =0.92; 95% confidence interval (CI), 0.65 to 1.32; P=0.66] (Figure 2) . MI Six studies assessed the rate of MI. There were 761 patients in the MIDCAB group and 749 patients in the DES group. There was no statistical heterogeneity between studies (Cochran Q =4.92, P=0.43; I²=0%, 95% CI, 0% to 61%).
In the random effects model, there was no significant differences in the rates of MI in the MIDCAB group compared to DES group (pooled OR =1.13, 95% CI, 0.62 to 2.06; P=0.69) (Figure 3 statistical heterogeneity between the six studies (Cochran Q =38.8, P=0<0.0001; I²=87.1%, 95% CI, 72.4% to 92.3%) (Figure 4) . In the random effect model, there was no significant difference in the MACCE rates between the CABG group and PCI groups (pooled OR =1.31; 95% CI, 0.58 to 2.95; P=0.52) ( Figure 5) . TVR Eight studies reported on the rate of TVR between the two groups. There were 999 patients in the CABG group and 1,803 patients in the PCI groups. There was no significant statistical heterogeneity between the eight studies (Cochran Q =3.47, P=0.84; I²=0%; 95% CI, 0% to 56.3%). In the random effect model, there was significant difference in the TVR rates between the CABG groups and PCI groups (pooled OR =0.27; 95% CI, 0.16 to 0.45; P<0.0001) (Figure 6 ).
Discussion
This systematic review and meta-analysis of three RCTs and nine cohort studies enrolling 7,710 participants is the most up to date meta-analysis on the subject. The results of the analysis suggest both MIDCAB and DES are effective strategies for revascularization of isolated LAD stenosis. However, DES compared to MIDCAB is associated with increased TVR.
The results of this meta-analysis substantiate those of a previously published meta-analysis by Kinnaird et al. (22) . The interpretation of this meta-analysis will need to take into consideration the fact that the DES technology used in several of the included studies is no longer representative of the contemporary percutaneous coronary intervention practice. However, this meta-analysis confirms the superiority of LIMA-to-LAD in terms of freedom from repeat re-intervention against both first-and secondgeneration DES making it an impressive benchmark against which all existing and future DES technologies must perform. Despite this, it will not be inappropriate to suggest that each case should be treated on their individual merits, and the information about significant excess of repeat TVR with DES strategy must feature in the informed consent.
There are several important caveats that must be acknowledged. First, as studies with different designs were included therefore some results of our meta-analysis have significant heterogeneities. Second, definitions of end points were different across included studies. Third, follow-up lengths were variable with majority of the studies reporting follow-up up to 1 year. Hence, the long-term durability of DES particularly second-generation DES versus MIDCAB remains undetermined. Fourth, it is important to point out the publication bias exaggerating the positive effects of MIDCAB could be a likely explanation for the superiority of MIDCAB over DES in terms of TVR as positive results have tendency to be published more likely than negative results. Fifth, data about the timing of intervention was not collected. The possibility of DES being offered preferentially to patients presenting with acute coronary syndrome and MIDCAB to elective patients in retrospective studies could also account for some of the perceived advantages of MIDCAB. Last and not the least, one could argue that the differences in TVR between DES and MIDCAB could be because of the difference in extent and complexity of coronary artery disease. The purists could argue that larger RCTs with longer followup are required to improve the evidence-base. However, at the same time, it is extremely important to mention that RCTs of impractical sizes with extremely long followup will be required to conclusively prove the superiority of any myocardial revascularization strategy or technique. Furthermore, such studies are unlikely to be performed because the rate of technological advancement particularly in the field of percutaneous coronary intervention is likely to make the results of such a trial obsolete.
This most up-to-date meta-analysis suggests that MIDCAB offers superior freedom from TVR with similar mortality, MI rate and MACCE compared to percutaneous intervention with DES for revascularization in patient with isolated proximal LAD stenosis.
